Definium Therapeutics, Inc.

Company DFTX

Last mentioned: 4d ago

Timeline

  1. Anticipated Readout

    Expected top-line data from the Phase III DT120 trial.

  2. Jefferies Analyst Note

    Jefferies issues high-conviction 65-75% probability for best-in-class efficacy.

  3. Phase III Initiation

    Global Phase III trial for DT120 begins enrollment.

  4. Phase II Success

    Definium publishes robust Phase II data for DT120.

Stories mentioning Definium Therapeutics, Inc. 1

Clinical Trials Bullish

Jefferies Bullish on Definium's DT120: 75% Odds for Best-in-Class Efficacy

Jefferies analysts have issued a high-conviction outlook on Definium Therapeutics' lead candidate, DT120, assigning a 65-75% probability that the drug will demonstrate best-in-class efficacy in its ongoing Phase III trials. This projection positions the company as a potential disruptor in its therapeutic category, significantly raising market expectations ahead of upcoming data readouts.

2 sources